Purpose: The aim of our study is to assess the pharmacokinetics and biodistribution of 68 Ga-PSMA-11 in patients suffering from primary prostate cancer (PC) by means of dynamic and whole-body PET/CT. Materials and methods: Twenty-four patients with primary, previously untreated PC were enrolled in the study. All patients underwent dynamic PET/ CT (dPET/CT) scanning of the pelvis and whole-body PET/CT studies with 68 Ga-PSMA-11. The evaluation of dPET/CT studies was based on qualitative evaluation, SUV calculation, and quantitative analysis based on two-tissue compartment modeling and a noncompartmental approach leading to the extraction of fractal dimension (FD). Results: A total of 23/24 patients (95.8%) were 68 Ga-PSMA-11 positive. In 9/24 patients (37.5%), metastatic lesions were detected. PC-associated lesions demonstrated the following mean values: SUV average = 14.3, SUV max = 23.4, K 1 = 0.24 (1/min), k 3 = 0.34 (1/min), influx = 0.15 (1/ min), and FD = 1.27. The parameters SUV average , SUV max , k 3 , influx, and FD derived from PC-associated lesions were significantly higher than respective values derived from reference prostate tissue. Time-activity curves derived from PC-associated lesions revealed an increasing 68 Ga-PSMA-11 accumulation during dynamic PET acquisition. Correlation analysis revealed a moderate but significant correlation between PSA levels and SUV average (r = 0.60) and SUV max (r = 0.57), and a weak but significant correlation between Gleason score and SUV average (r = 0.33) and SUV max (r = 0.28).
T o date, the contribution of conventional imaging modalities in staging and management of men with prostate cancer (PC) is smaller than in other common cancers. [1] [2] [3] [4] [5] [6] Imaging studies exhibit a low positivity in clinically localized disease (with the exception of patients with PSA levels ≥20 ng/mL or Gleason scores ≥8) and a low sensitivity in detecting lymph node metastases. With the exception of 18 F-choline and 11 C-acetate PET/CT, which demonstrated a high sensitivity in the biochemical relapse of PC, [7] [8] [9] the performance of most imaging approaches in detecting metastatic or recurrent PC in the setting of biochemical relapse is also not high. 4, [10] [11] [12] [13] [14] Therefore, the development and introduction into clinical practice of new imaging modalities that carry high sensitivity and specificity in PC detection is of outmost importance.
The first results of the novel agent 68 Ga-labeled Glu-urea-Lys-(Ahx)-HBED-CC ( 68 Ga-PSMA-11) have been very satisfying, rendering the addition of 68 Ga-PSMA-11 PET/CT to the diagnostic armamentarium a very promising approach in PC staging. 10, [15] [16] [17] This tracer carries some very desirable characteristics for the imaging approach of PC: specific targeting of prostate-specific membrane antigen (PSMA), fast blood clearance, low background activity, and a relative short physical half-life of the isotope (68.3 min). 18, 19 Dynamic PET/CT (dPET/CT) is a modality that allows registration of pharmacokinetic information over time, unlike classical whole-body PET/CT protocols that enable the acquisition of patient images only at one time point after tracer injection. Compartment analysis provides the possibility to assess dedicated aspects of tracer kinetics, which are associated with molecular biological data, and represents simplifications of actual complicated in vivo processes. In this sense, the two-tissue compartment model performed in the present study is an approximation of the underlying biological system regarding 68 Ga-PSMA-11 metabolism. The application of twotissue compartment modeling in the 68 Ga-PSMA-11 dynamic PET data leads to the extraction of four transport rates (K 1 , k 2 , k 3 , k 4 ), which describe the tracer exchange between plasma and tissue. In particular, K 1 and k 2 reflect the forward and reverse transport of the radiotracer between plasma and the reversible compartment, which involves free tracer in interstitial fluid. Respectively, k 3 and k 4 account for forward and reverse transport between the reversible and trapped compartment, which involves the PSMA-specific part of tracer metabolism, leading to the assumption that the constant rate k 3 is associated with tracer binding on the receptor (PSMA) and its internalization, and k 4 with dissociation of the tracer from the receptor and externalization. 20, 21 This model has been used by our group for the pharmacokinetic analysis of 68 Ga-PSMA-11 studies in patients with biochemical relapse of PC. 20 The aim of this study is to evaluate the biodistribution and pharmacokinetics of 68 Ga-PSMA-11 in patients with primary PC by means of dynamic and whole-body PET/CT. The correlation between PSA levels and 68 Ga-PSMA-11 PET parameters is also investigated.
PATIENTS AND METHODS

Patients
Twenty-four patients suffering from primary, previously untreated PC were enrolled in the study. Their median age was 69 years (range = 43-84 years). The median PSA value was 24.1 ng/mL (range = 3.2-200.0 ng/mL). Gleason score was available in 21/24 patients (median = 7; range = 7-9). Table 1 presents analytically the characteristics of the patients investigated. The analysis was conducted in accordance to the Declaration of Helsinki with institutional approval.
Data Acquisition
The patients were intravenously administered with 68 Ga-PSMA-11, the 68 Ga-labeled HBED-CC conjugate of the PSMAspecific pharmacophore Glu-NH-CO-NH-Lys(Ahx), which was synthesized and radiolabeled as published previously (range = 69-352 MBq, median = 268 MBq). [22] [23] [24] Data acquisition consisted of two parts: the dynamic part (dPET/CT studies) and the static part (whole-body PET/CT). dPET/CT studies were performed over the pelvic area and the lower abdomen (two bed positions, 44 cm) for 60 minutes using a 24-frame protocol (10 frames of 30 s, 5 frames of 60 s, 5 frames of 120 s, and 8 frames of 300 s). Whole-body static imaging was performed in all patients with an image duration of 2 minutes per bed position for the emission scans after the end of the dynamic acquisition. A dedicated PET/CT system (Biograph mCT, 128S; Siemens Co., Erlangen, Germany) with an axial field of view of 21.6 cm with TruePoint and TrueV, operated in a three-dimensional mode, was used. A low-dose attenuation CT (120 kV, 30 mA) was used for the attenuation correction of the dynamic emission PET data and for image fusion. A second low-dose CT from the skull to the knees (120 kV, 30 mA) was performed after the end of the dynamic series. All PET images were attenuation-corrected and an image matrix of 400 Â 400 pixels was used for iterative image reconstruction. Iterative image reconstruction was based on the ordered subset expectation maximization algorithm (OSEM) with 6 iterations and 12 subsets. The reconstructed images were converted to SUV images based on the formula 25 : SUV = tissue concentration (Bq/g)/ (injected dose (Bq)/body weight (g)). The SUVs 55 to 60 minutes post-injection were used for quantification of tracer data.
Data Analysis
Data analysis and evaluation was based on visual analysis of the PET/CT scans, semiquantitative evaluation based on SUV calculations, and quantitative analysis. Qualitative analysis was based on visual assessment of the PET/CT scans. Two nuclear medicine physicians (CS, ADS) evaluated the tracer accumulating areas on transaxial, coronal, and sagittal images. In particular, areas presenting with significantly enhanced 68 Ga-PSMA-11 uptake, apart from those in which an increased tracer uptake is considered physiological, were considered indicative for PC involvement. PC-associated lesions were classified in the following categories: primary tumors (PC), lymph node metastases, bone metastases, and soft tissue metastases.
Semiquantitative evaluation was based on volumes of interest (VOIs) and on subsequent calculation of SUV. VOIs were drawn with an isocontour mode (pseudo-snake) and were placed over the PC-associated lesions, and over regions of the prostate gland that showed no pathological tracer accumulation and, thus, served as reference. 26 SUVs were calculated in the majority of lesions. All SUVs were assessed during the whole-body/static acquisition, 80 to 90 minutes p.i. However, pelvic lesions' SUVs were calculated at two time points, at the end of the dynamic PET acquisition (55-60 min p.i.) and during the whole-body/static acquisition (80-90 min p.i.), to assess changes in tracer uptake at different time points. Lesions that were <2 mm or without clearly delineated margins were not evaluated.
The quantitative evaluation of the dynamic PET data was performed with PMOD software (PMOD Technologies Ltd., Zürich, Switzerland). It was based on irregular VOIs, drawn with an isocontour mode (pseudo-snake), placed over PC-associated lesions. 26 Time-activity curves (TACs) were created using VOIs. Only lesions located in the anatomic area of the pelvis, where dPET/ CTwas performed, were evaluated quantitatively. A detailed quantitative evaluation of tracer kinetics was performed based on twotissue compartment modeling. 27, 28 The accurate measurement of the input function requires arterial blood sampling. However, it can be retrieved simplified and noninvasively from the image data with good accuracy according to methods already reported in literature and performed previously from our group. 29, 30 For this reason, at least seven consecutive ROIs were placed over the common iliac artery to obtain the blood data for 68 Ga-PSMA-11. The recovery coefficient was 0.85 for a diameter of 8 mm. The application of two-tissue compartment modeling leads to the extraction of the parameters K 1 , k 2 , k 3 , and k 4 . In this study, the constants K 1 , k 2 , k 3 , and k 4 were calculated taking into account the vascular fraction (V B ) in a VOI as an additional variable. The model parameters were accepted when K 1 , k 2 , k 3 , and k 4 were <1 and V B >0. The unit for the rate constants K 1 , k 2 , k 3 , and k 4 is 1/min, whereas V B is associated with the volume of blood exchanging with tissue. After compartmental analysis, we calculated the global influx (K i ) from the compartment data using the formula:
. In addition to creating VOIs over foci indicative of malignant involvement, we also created VOIs over normal prostate tissue (reference tissue). The values extracted from reference tissue were then compared to the respective values of PC involvement.
Apart from compartmental analysis, a noncompartment model was used to calculate the fractal dimension (FD). FD is a parameter of heterogeneity based on chaos theory. The values of FD vary from 0 to 2 showing the deterministic or chaotic biodistribution of the 68 Ga-PSMA-11 activity over time. 31 Data were statistically evaluated using the STATA/SE 12.1 (StataCorp) software on an Intel Core (2·3.06 GHz, 4 GB RAM) running with Mac OS X 10.8.4 (Apple Inc., Cupertino, CA). The statistical evaluation was performed using descriptive statistics, box plots, Wilcoxon rank-sum test, and Spearman rank correlation analysis. The results were considered significant for P less than 0.05 (P < 0.05).
RESULTS
Whole-Body PET/CT Studies Visual Evaluation
In 23/24 patients, at least one PC-associated lesion was detected, leading to a detection rate of 95.8% ( Figs. 1 and 2 ). Normal radiotracer biodistribution was demonstrated in the lacrimal Ga-PSMA-11 PET/CT of a 66-year-old PC patient with a PSA of 27 ng/mL. Whole-body maximum intensity projection (MIP) (A) reveals the primary tumor (arrow) and two skeletal metastases in the 9th thoracic vertebra and 7th left rib (arrows). Normal biodistribution of the tracer in lacrimal glands, salivary glands, nasal mucosa, liver, spleen, bowel, kidneys, and bladder. Transaxial PET/CT at the pelvic level (B) shows the primary tumor in the left prostate lobe (arrow). Transaxial PET/CT at the thoracic level (C) shows the osseous metastasis in the 9th thoracic vertebra (arrow).
glands, salivary glands, nasal mucosa, liver, spleen, bowel, kidneys, and bladder. One patient demonstrated tracer uptake neither in PC-associated lesions nor in tissues, where physiological uptake is expected. Eight patients demonstrated multifocal tracer uptake in the prostate gland, in three of which the precise number of PC lesions could not be calculated. In one patient, the extent of lymph node and bone metastatic involvement was very large, rendering the exact calculation of metastatic osseous and lymph node metastases practically impossible. Metastatic disease was detected in nine patients, and five of them had already been examined with conventional imaging modalities (CT and/or MRI) before the 68 Ga-PSMA-11 PET/CT. Four of these five preexamined subjects were positive for metastases based on conventional imaging, whereas one was negative. Interestingly, in this subgroup of 5 patients, only 4 of the total 19 68 Ga-PSMA-11-positive metastatic lesions were depicted in the conventional modalities. A total of 88 PC-associated lesions were evaluated. In particular, 26 lesions corresponded to primary prostatic tumors, 34 to lymph node metastases, 26 to bone metastases, and 2 to soft tissue metastases (Table 1) .
Semiquantitative Evaluation
A total of 72 of the 88 lesions were semiquantitatively (SUV) evaluated. In particular, SUVs were calculated for 26 primary prostatic tumors, 16 lymph node metastases, and 30 bone metastases (Fig. 3) . According to Wilcoxon rank-sum test, lesions' SUVs were significantly higher than respective values derived from reference prostate gland. Spearman rank correlation analysis showed that PSA levels correlated significantly with PC-associated lesions' SUV average (r = 0.60, P < 0.0001) and SUV max (r = 0.57, P < 0.0001). Moreover, a weak but significant correlation was demonstrated between Gleason score and SUV average (r = 0.33, P < 0.05) and SUV max (r = 0.28, P < 0.05). 
Dynamic PET/CT Studies of the Pelvis
Fifty-eight 68 Ga-PSMA-11 pelvic lesions were quantitatively evaluated by means of dPET/CT (26 primary tumors, 13 lymph node metastases, and 19 osseous metastases). The values of SUVs and kinetic parameters derived from PC-associated lesions and from reference prostate gland are depicted in Table 2 . Wilcoxon ranksum revealed that, besides SUV average and SUV max , the parameters k 3 , influx, V B , and FD were significantly higher in PC-related lesions than in reference tissue. Regarding the different PC recurrence sites, Wilcoxon rank-sum test revealed that osseous metastatic lesions had higher FD values than primary tumors and lymph node metastases. Furthermore, k 3 from osseous lesions was higher than k 3 from lymph node metastases (P < 0.05) (Fig. 4) . No significant correlations were observed between kinetic parameters and PSA or Gleason score.
Moreover, we calculated the SUVs of the pelvic lesions at two time points: at the end of the dynamic PET acquisition (55-60 min p.i.; "early" SUVs) and during the whole-body/static acquisition (80-90 min p.i.; "late" SUVs). This evaluation revealed that both SUV average and SUV max increased at late acquisition times. In particular, the mean value of "early" SUV average was 14.9 (median = 12.4), whereas the mean value of "late" SUV average was 17.8 (median = 15.8). Respectively, the mean value of "early" SUV max was 24.4 (median = 19.6), whereas the mean value of "late" SUV max was 29.0 (median = 24.5).
Dynamic PET/CT scanning led also to the extraction of time-activity curves (TACs), which show the activity concentration of 68 Ga-PSMA-11 in the selected VOI during the 60 minutes of dPET/CT acquisition. Figure 5 demonstrates the resulting TACs derived from a primary tumor, an osseous metastasis, a lymph node metastasis, and reference prostate tissue. The curves show that 68 Ga-PSMA-11 concentration increases in the PC-associated lesions in comparison to normal prostate.
Spearman rank correlation analysis was performed between 68 Ga-PSMA-11 quantitative parameters. The strongest correlations (P < 0.05) were found between FD and SUV average (r = 0.93), FD and SUV max (r = 0.87), FD and influx (r = 0.77), and between influx and SUV average (r = 0.76), influx and SUV max (r = 0.75), and influx and K 1 (r = 0.82) ( Table 3) .
DISCUSSION
The first satisfying results from the introduction of 68 Ga-PSMA-11 in PC diagnostics have rendered PET imaging with this novel agent highly promising. [15] [16] [17] In this analysis, we studied the detection rate and pharmacokinetics of 68 Ga-PSMA-11 in a group of patients suffering from primary, histologically confirmed PC, by means of dynamic and whole-body PET/CT.
Regarding whole-body PET/CT studies, all patients but one were 68 Ga-PSMA-11 positive (95.8%). This high detection rate is of no surprise because the radioligand, which specifically binds to the prostate-specific membrane antigen (PSMA), is expressed practically in all PCs. 3, 32, 33 Correlation analysis revealed that PSA plasma levels correlated positively with tracer uptake in PC-associated lesions, as reflected by SUV average (r = 0.60) and SUV max (r = 0.57), a result in agreement with previous results from our group in patients with biochemical recurrence of PC. 20 Furthermore, 68 Ga-PSMA-11 uptake, measured by SUV average and SUV max , correlated weak but significantly with Gleason score. This result is in line with the findings of Rowe et al., who also demonstrated a significant, positive correlation between Gleason score and SUV max of the radiotracer 18 F-DCFBC that also targets PSMA in a group of 13 patients with primary PC. 34 A potential explanation for these weak/moderate correlations between 68 Ga-PSMA-11 uptake and the previously mentioned parameters could be the heterogeneity of PSMA expression in PC, also in correlation with PSA levels and Gleason score, which has been highlighted in some studies. 35, 36 Dynamic PET/CT imaging revealed that PC-associated lesions demonstrate higher 68 Ga-PSMA-11 uptake (SUVs), higher The SUVs are derived from the 72 lesions, which were evaluated. The kinetic parameters are derived after application of two-tissue compartment modeling in the -dPET/CT data from the pelvis (58 lesions). The values of parameters K 1 , k 2 , k 3 , k 4 , and influx are 1/min. SUV, V B , and FD have no unit. *Significant probabilities (P < 0.05).
FIGURE 4.
Box plots of parameters K 1 , k 3 , and influx derived from primary PC lesions (left row), lymph node metastases (middle row), and osseous metastases (right row). k 3 from osseous metastases is significantly higher than k 3 from lymph node metastases (P < 0.05). Otherwise, no other statistically significant differences are depicted between sites of PC involvement regarding these parameters. The values of parameters K 1 , k 3 , and influx are 1/min.
blood volume (V B ), higher forward transport rate between the reversible and trapped compartment, which is associated with higher receptor binding and internalization according to our hypothesis (k 3 ), and higher influx than reference prostate gland. The fact that malignant lesions demonstrate higher kinetic values than reference tissue or benign lesions has been highlighted for various tumors with different tracers. 30, [37] [38] [39] [40] The lesions' TACs showed a steadily increasing tracer accumulation during the 60 minutes of dynamic PET acquisition (Fig. 5) . Furthermore, the comparison of SUVs in the last frame of dynamic acquisition (55-60 min p.i.) and in the static/whole-body late images (80-90 min p.i.) revealed an increase of tracer uptake at late acquisition times, which has been described in a previous study even for longer time intervals. 41 The finding that 68 Ga-PSMA-11 shows a high receptor binding and internalization, and accumulates increasingly in the primary PC-associated lesions is in good agreement with preclinical data of the tracer 24 and previously published data from our group regarding the behavior of 68 Ga-PSMA-11 in pre-treated PC patients with biochemical recurrence. 20 The here presented findings confirm the previous results also in patients suffering from primary PC and imply a potential efficacy of anti-PSMA approaches in primary PC-associated lesions, especially considering the promising results of the radioligand-based anti-PSMA therapy with 177 Lu-PSMA-617 42 and 131 I-MIP-1095. 43 This study has some limitations. Firstly, the number of patients enrolled is small. Secondly, most but not all of the 68 Ga-PSMA-11-positive findings on PET/CT were histopathologically confirmed. Nevertheless, the so far collected data regarding the 68 Ga-PSMA ligand imply that tracer-avid PET lesions with morphological correlation have to be considered as positive for PC involvement. 44 Finally, an expansion of the dynamic PET acquisition at later time points (for example at 2 h or 3 h p.i.) would provide more robust data regarding 68 Ga-PSMA-11 accumulation in PC-associated regions over time, a limitation partially compensated by calculating SUVs of pelvic lesions at the end of dynamic PET acquisition and during the static studies.
CONCLUSION
In the present study, the diagnostic efficacy of 68 Ga-PSMA-11 PET/CT in primary PC was confirmed with an overall detection rate of 95.8%. A positive correlation was demonstrated between SUVs of 68 Ga-PSMA-11-positive lesions and PSA plasma levels, and Gleason score. Dynamic PET/CT studies of the pelvis demonstrated that tracer uptake in PC-associated lesions is increasing FIGURE 5. Representative time-activity curves (TACs) derived after application of two-tissue compartment modeling in the dynamic PET/CT data. The TACs are derived from VOIs drawn over a primary PC (first row), an osseous metastasis (second row), a lymph node metastasis (third row), and reference prostate gland (fourth row). The curves derived from PC-associated lesions show that 68 Ga-PSMA-11 accumulates increasingly in the respective VOIs in the 60 minutes of dynamic PET acquisition. On the other hand, the TAC derived from normal prostate tissue demonstrates a lower accumulation of 68 Ga-PSMA-11 during dynamic PET acquisition. The values of parameters K 1 , k 3 , and influx are 1/min. SUV and FD have no unit. during the 60 minutes of dynamic PET acquisition. The application of two-tissue compartment modeling revealed a high receptor binding and internalization of 68 Ga-PSMA-11 in the PC-associated lesions.
